GSK and Actelion drop insomnia treatment

pharmafile | January 30, 2011 | News story | Research and Development |  Actelion, GSK, insomnia 

Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.

Almorexant a dual orexin receptor antagonist,has been discontinued following a review of data from additional clinical studies which were conducted to gather further data on its clinical profile, “including the tolerability profile”.

The companies nevertheless say they “remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications”. 

Actelion has grown very rapidly over the last few years thanks to its pulmonary arterial hypertension blockbuster Tracleer (bosentan), but is needs other drugs to maintain and expand its revenues.

Advertisement

Tracleer brings in the vast majority of the company’s revenues, but faces patent expiry from 2015.

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Five Facts about sleep and mental health

1 Rapid Eye Movement (REM) sleep enhances creative thinking and helps the brain form connections …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

The Gateway to Local Adoption Series

Latest content